-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with hemophilia A (PwHA) lack factor VIII (FVIII), leading to spontaneous and traumatic bleeding, most commonly joint, muscle and soft tissue bleeding; intracranial bleeding can be life-threatening.
Subcutaneous injection of bispecific humanized monoclonal antibody emicizumab for prevention can promote effective hemostasis in patients with hemophilia A.
prevention
This article reports a pooled analysis of 4 phase III studies (HAVEN 1, HAVEN 2, HAVEN 3, and HAVEN 4) to clarify the long-term efficacy, safety, and pharmacokinetic characteristics of imiizumab .
Clarify the long-term efficacy, safety and pharmacokinetic characteristics of imiizumab
The analysis covered a total of 401 pediatric and adult PwHA patients with or without factor VIII (FVIII) inhibitors.
Annual bleeding rate
Annual bleeding rateAs of May 15, 2020, the overall intermediate validity period is 120.
The overall intermediate duration was 120.
Adverse events
Adverse eventsImiizumab was well tolerated, and no subject was discontinued due to adverse events more than 5 times previously reported .
Imiizumab was well tolerated, and no subject interrupted the blood vessel of the thrombosis due to adverse events exceeding 5 times previously reported
In summary, this analysis analyzed 970.
Amy natalizumab prevention method can effectively maintain a low rate of bleeding in patients of all ages PwHA or without the use of FVIII inhibitors, and well tolerated, not the emergence of new security risks Amy natalizumab prevention The method can effectively maintain a low bleeding rate in PwHA patients of all ages who use or do not use FVIII inhibitors, and is well tolerated, and there are no new safety hazards.
Original source:
Michael U.
org/10.
1182/blood.
2020009217" target="_blank" rel="noopener">Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies in this message